Christophe Lallemand

GAAP‐1: a transcriptional activator of p53 and IRF‐1 possesses pro‐apoptotic activity

Michael G Tovey, Marta Palmieri, Christophe Lallemand, 2002, EMBO reports.

Immunogenicity and other problems associated with the use of biopharmaceuticals

Michael G Tovey, Christophe Lallemand, C. Lallemand, 2011, Therapeutic advances in drug safety.

Safety, Tolerability, and Immunogenicity of Interferons

Christophe Lallemand, C. Lallemand, Michael G. Tovey, 2010, Pharmaceuticals.

Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals.

Michael G Tovey, Christophe Lallemand, C. Lallemand, 2012, Bioanalysis.

Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists.

Michael G Tovey, S. Alzabin, P. Charles, 2011, Journal of immunological methods.